Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™

NCT03936426 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Meningioma

Interventions

DRUG: Cu-64 SARTATE and Cu-67 SARTATE

Sponsor

Clarity Pharmaceuticals Ltd